
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Parkinson’s Disease Treatment Market**

According to Intelli, the U.S. Parkinson’s Disease Treatment Market size was valued at USD 1,947.9 Million in 2024 and is projected to reach USD 2,848.34 Million by 2032, growing at a CAGR of 5.39% from 2025 to 2032.



Parkinson’s Disease (PD) is a progressive neurological disorder that primarily affects movement, causing tremors, stiffness, slowness of motion, and balance difficulties. PD develops when dopamine-producing neurons in a part of the brain called the substantia nigra begin to degenerate or die. Although the exact cause of this neuronal damage is still unknown, research suggests that both genetic and environmental factors play a role. In some cases, inherited genetic mutations may increase the risk, while in others, exposure to environmental toxins, head trauma, or other external influences may contribute. Although there is currently no cure for PD, several effective treatment options are available that can greatly enhance quality of life and help manage symptoms. One of the most common treatments is medication, particularly levodopa, which the brain converts into dopamine to replenish declining levels. Dopamine agonists are also used to mimic the effects of dopamine in the brain, helping to improve movement and reduce symptoms like tremors and stiffness. For patients whose symptoms are not adequately controlled with medication alone, Deep Brain Stimulation (DBS) may be recommended. This surgical procedure involves implanting electrodes in specific parts of the brain, which deliver controlled electrical impulses to regulate abnormal activity and reduce motor symptoms. Emerging treatments, including gene therapy, stem cell research, and novel drug developments, offer promising directions for slowing disease progression and improving outcomes. PD challenges both patients and caregivers, but with a comprehensive, personalized approach, many can lead fulfilling lives despite the diagnosis.

**U.S. Parkinson’s Disease Treatment Market Definition**

**​**The U.S. Parkinson’s Disease treatment market encompasses a range of therapeutic interventions aimed at managing the symptoms of PD. The market comprises a variety of pharmaceutical treatments, including levodopa/carbidopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and anticholinergics, along with advanced therapeutic options such as DBS. The U.S. Parkinson’s Disease treatment market is a dynamic and evolving A close-up of hands holding a tablet and a pen

Description automatically generatedsector, with ongoing research and development efforts aimed at improving patient outcomes and addressing unmet medical needs.

**U.S. Parkinson’s Disease Treatment Market Overview**

​The U.S. Parkinson’s Disease treatment market is experiencing significant growth, driven by several key factors. A leading driver of the U.S. Parkinson’s Disease treatment market is the growing aging population. As the number of individuals aged 65 and older continues to rise, the prevalence of Parkinson’s Disease also increases, given that advancing age is one of the most significant risk factors for developing the condition. Another critical driver is the continuous advancement in therapeutic options. The development of novel therapies, including gene and stem cell treatments, holds promise for modifying disease progression and enhancing patient outcomes. Technological advancements are playing a crucial role in transforming Parkinson’s Disease management. The adoption of wearable devices, such as smartwatches and motion sensors, allows for continuous monitoring of symptoms like tremors, mobility, and sleep patterns. This real-time data provides valuable insights into a patient’s condition, enabling healthcare providers to make more precise, personalized treatment adjustments. Additionally, the identification of biomarkers such as the alpha-synuclein seeding amplification assay (SAA) is paving the way for earlier and more precise diagnosis of Parkinson’s Disease. This advancement holds the potential to significantly reshape the treatment landscape by enabling earlier intervention, better monitoring of disease progression, and the development of more targeted and effective therapies. In addition, substantial investments in research and development (R&D) are fueling the growth of the Parkinson’s Disease treatment market by driving innovation and the development of new therapies. Government agencies, pharmaceutical companies, and private organizations are allocating significant funding to explore various aspects of the disease. With continuous advancements in R&D, there is a growing potential to unlock novel treatment options, expand the available therapeutic options, and address the unmet needs of Parkinson’s patients.

**U.S. Parkinson’s Disease Treatment Market segmentation**

**​**The U.S. Parkinson’s Disease treatment market is segmented across several dimensions, each highlighting unique aspects of patient care and therapeutic approaches.

**U.S. Parkinson’s Disease Treatment Market, By Drug Class**

* **Carbidopa-Levodopa**
* A close-up of hands holding a tablet and a pen

  Description automatically generated**MAO-B Inhibitors**
* **Dopamine Agonists**
* **COMT Inhibitors**
* **Anticholinergics**

In the U.S. Parkinson’s Disease treatment market, Carbidopa-Levodopa dominates the drug class segment, holding a significant share due to its long-established effectiveness in managing the core symptoms of Parkinson’s, such as tremors, rigidity, and bradykinesia. Following closely are MAO-B inhibitors, which inhibit the breakdown of dopamine, contributing to their growing adoption, particularly in the early stages of the disease. These inhibitors hold around 15-20% of the market share. Dopamine Agonists, which mimic dopamine’s effects on the brain, are widely used as adjuncts to levodopa therapy and are gaining traction in both early and advanced stages of Parkinson’s, representing approximately 12-18% of the market. COMT Inhibitors, which enhance the duration of levodopa's effects by inhibiting its breakdown, account for approximately 10-12% of the market, particularly when used in combination therapies. On the other hand, Anticholinergics, although less frequently prescribed today, continue to play a key role in managing symptoms. Together, these drug classes form the backbone of Parkinson’s treatment, with Carbidopa-Levodopa leading the way in market share and clinical application.

**U.S. Parkinson’s Disease Treatment Market, By Treatment Type**

* **Medication**
* **Surgical Therapy**
* **Carbidopa/Levodopa Enteral Suspension**

In the U.S. Parkinson’s Disease treatment market, medication remains the most widely used treatment option, capturing the largest share of the market. Surgical therapy, particularly Deep Brain Stimulation (DBS), has emerged as a crucial option for patients with advanced Parkinson’s whose symptoms are not sufficiently managed by medication. The Carbidopa/Levodopa Enteral Suspension offers a continuous drug delivery system for more consistent symptom control in patients with advanced stages of Parkinson’s. This treatment modality is gaining traction, capturing about 10-12% of the market, as it provides a more stable and effective way to manage motor fluctuations.

A close-up of hands holding a tablet and a pen

Description automatically generated

**U.S. Parkinson’s Disease Treatment Market, By Route of Administration**

* **Oral**
* **Injectable**
* **Transdermal**

In the U.S. Parkinson’s Disease treatment market, oral administration remains the most common and dominant route, capturing the largest share. Medications such as Carbidopa-Levodopa and dopamine agonists are primarily delivered in oral forms like tablets and capsules. Injectable therapies, including continuous infusion systems and biologic treatments, are growing in prominence for patients requiring more precise and sustained medication delivery. Transdermal treatments, such as patches that provide a steady release of medication like rotigotine, are gaining popularity for their ease of use and consistent delivery. These different routes of administration reflect the variety of treatment options available to meet the diverse needs of Parkinson’s patients.

**U.S. Parkinson’s Disease Treatment Market, By Distribution Channel**

* **Hospital Pharmacy**
* **Specialty Pharmacy**
* **Online Pharmacy**

In the U.S. Parkinson’s Disease treatment market, hospital pharmacies are the primary distribution channel, accounting for the largest share. This is due to the critical care and specialized treatment required for Parkinson’s patients, particularly in hospitals where advanced therapies like DBS and injectable treatments are administered. Specialty pharmacies also play a significant role, particularly in the distribution of high-cost or specialized medications, such as Carbidopa/Levodopa Enteral Suspension and biologic therapies. Online pharmacies are becoming increasingly important, providing convenient access to medications for patients, especially those in remote areas or with limited mobility. Together, these distribution channels support the wide-reaching accessibility of Parkinson’s Disease treatments across various patient demographics.

A close-up of hands holding a tablet and a pen

Description automatically generated**Key Players**

The “U.S. Parkinson’s Disease treatment market" study report will provide valuable insight emphasizing the U.S. market. The major players in the market Supernus Pharmaceuticals, Biogen Inc., Intrance Medical Systems, Neurocrine Biosciences, AbbVie, Novartis AG, Acorda Therapeutics, Amneal Pharmaceuticals, Medtronic, Valeant Pharmaceuticals, H. Lundbeck A/S, GSK, Merck & Co., Inc., Teva Pharmaceuticals Industries Ltd., US World Meds, Impax Laboratories among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In February 2025, the FDA approved Onapgo, a continuous under-the-skin infusion treatment that helps manage “off” episodes, times when Parkinson’s symptoms return between doses of medication.
* In 2025, the FDA approved Medtronic’s Adaptive Deep Brain Stimulation and BrainSense Electrode Identifier, representing a major step forward in personalized treatment for Parkinson’s Disease patients.
* In 2024, Amneal Pharmaceuticals resubmitted its FDA application for IPX203, a new oral form of carbidopa/levodopa designed to treat Parkinson’s Disease.
* In 2024, Roche shared encouraging trial results for prasinezumab, an antibody treatment designed to slow the progression of Parkinson’s Disease.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. Parkinson’s Disease treatment market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape U.S. Parkinson’s Disease treatment market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF U.S. PARKINSON’S DISEASE TREATMENT MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. PARKINSON’S DISEASE TREATMENT MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS**

5.1 Overview

5.2 Carbidopa-Levodopa

A close-up of hands holding a tablet and a pen

Description automatically generated5.3 MAO-B Inhibitors

5.4 Dopamine Agonists

5.5 COMT Inhibitors

5.6 Anticholinergics

**6 U.S. PARKINSON’S DISEASE TREATMENT MARKET, BY TREATMENT TYPE**

6.1 Overview

6.2 Medication

6.3 Surgical Therapy

6.4 Carbidopa/Levodopa Enteral Suspension

**7 U.S. PARKINSON’S DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION**

7.1 Overview

7.2 Oral

7.3 Injectable

7.4 Transdermal

1. **U.S. PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL**
   1. Overview
   2. Hospital Pharmacy
   3. Specialty Pharmacy
   4. Online Pharmacy
2. **U.S. PARKINSON’S DISEASE TREATMENT MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. A close-up of hands holding a tablet and a pen

      Description automatically generated Company Market Ranking
   3. Key Developments Strategies
3. **COMPANY PROFILES**

**10.1 Supernus Pharmaceuticals**

* + 1. Overview
    2. Financial Performance
    3. Product Outlook
    4. Key developments
  1. **Biogen Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Intrance Medical Systems**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Neurocrine Biosciences**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **AbbVie**
     1. Overview
     2. A close-up of hands holding a tablet and a pen

        Description automatically generatedFinancial Performance
     3. Product Outlook
     4. Key developments
  5. **Novartis AG**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Acorda Therapeutics**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Amneal Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **Medtronic**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Valeant Pharmaceuticals**
     1. Overview
     2. A close-up of hands holding a tablet and a pen

        Description automatically generatedFinancial Performance
     3. Product Outlook
     4. Key developments
  3. **H. Lundbeck A/S**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **GSK**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Merck & Co., Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Teva Pharmaceuticals Industries**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **US World Meds**
     1. Overview
     2. Financial Performance
     3. A close-up of hands holding a tablet and a pen

        Description automatically generatedProduct Outlook
     4. Key developments
  8. **Impax Laboratories**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

12.1 Related Research